20 / 32
Tumour T790M-positive
Plasma T790M-positive
No. at risk
Osimertinib
1.0
0.8
0.6
0.4
0.2
0
0
3
6
9
12
15
18
Months
279
140
240
93
162
44
88
17
50
7
13
1
0
0
No. at risk
Osimertinib
Platinum-
pemetrexed
Platinum-
pemetrexed
1.0
0.8
0.6
0.4
0.2
0
0
3
6
9
12
15
18
116
56
95
39
63
13
35
5
20
2
5
1
0
0
Months
Probability of
progression-free survival
Probability of
progression-free survival
AURA 3: T790M plasma
vs
tissue
Wu Y-L, et al. WCLC 2016
PFS 10.1 vs 4.4 m (HR=0.30)
ORR= 71%
vs
31%
PFS 8.2 vs 4.2 m (HR=0.42)
ORR= 77%
vs
39%